DIFLUOROMETHYLORNITHINE FOR ARSENO-RESISTANT TRYPANOSOMA BRUCEI GAMBIENSE SLEEPING SICKNESS
暂无分享,去创建一个
F. Milord | J. Pepin | C. Guern | F. Milord | P. J. Schechter | C. Guern | J. Pépin | P. Schechter | François Milord | J. Pepin
[1] B. Greenwood,et al. The pathogenesis of sleeping sickness. , 1980, Transactions of the Royal Society of Tropical Medicine and Hygiene.
[2] L Haller,et al. Clinical and pathological aspects of human African trypanosomiasis (T. b. gambiense) with particular reference to reactive arsenical encephalopathy. , 1986, The American journal of tropical medicine and hygiene.
[3] P. Schechter,et al. Kinetics of α‐difluoromethylornithine: An irreversible inhibitor of ornithine decarboxylase , 1981, Clinical pharmacology and therapeutics.
[4] P. McCann,et al. Polyamine metabolism: a potential therapeutic target in trypanosomes. , 1980, Science.
[5] A. Sjoerdsma,et al. Difluoromethylornithine, an effective new treatment of Gambian trypanosomiasis. Results in five patients. , 1987, The American journal of medicine.
[6] A. Sjoerdsma,et al. Treatment of gambiense sleeping sickness in the Sudan with oral DFMO (DL-alpha-difluoromethylornithine), an inhibitor of ornithine decarboxylase; first field trial. , 1985, Transactions of the Royal Society of Tropical Medicine and Hygiene.
[7] P. McCann,et al. New drug combination for experimental late-stage African trypanosomiasis: DL-alpha-difluoromethylornithine (DFMO) with suramin. , 1984, The American journal of tropical medicine and hygiene.
[8] A. Sjoerdsma,et al. Chemotherapeutic implications of polyamine biosynthesis inhibition , 1984, Clinical pharmacology and therapeutics.
[9] D. Ray,et al. Diagnosis of African and American trypanosomiases. , 1985 .